Videos

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Explore emerging multiple sclerosis treatments, from brain-protective targets and remyelination to CAR-T, stem cell transplants, and more accessible anti-CD20 options.

Experts explore emerging multiple sclerosis treatments, from brain-protective PDE4 inhibitors and remyelination to CAR T, stem cell transplant, and easier anti-CD20 options.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

Oncology pharmacists can advocate and communicate clearly to boost recognition, strengthen care teams, and improve cancer treatment outcomes.

Laxmi Mehta, MD, discusses widespread patient unawareness of nonstatin cholesterol therapies, common statin misconceptions, and the critical role pharmacists play in bridging the lipid treatment knowledge gap.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

The Role of Clinical Pharmacists – Best Practices and Early Execution

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

Finibrutinib’s phase 3 MS results hint at new hope for relapsing and progressive disease, as experts weigh safety and monitoring.

Why MS relapses aren’t the whole story: experts explain PIRA, the push for remyelination, and how BTK inhibitors may reach the CNS.

TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Allison Hill, PharmD, RPh, underscores how pharmacists can sustain vaccination momentum through community partnerships.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Counseling Patients With oHCM––Using Data to Instill Confidence

Treatment Options for oHCM – Aligning Guidance With Real-World Data to Improve Outcomes

Pharmacists enhance pneumococcal vaccination integration through routine screenings, flexible access, and team-based approaches for improved patient care.

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

Allison Hill, PharmD, RPh, emphasizes that it is not too late for flu vaccination and highlights how pharmacists can address vaccine fatigue.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

MS experts say MRI and current trial endpoints miss “smoldering” progression; emerging biomarkers, 7T imaging, PROs, and CNS-penetrant therapies aim to close gaps.

Learn how hidden neuroinflammation drives MS progression, why MRI may miss it, and how rim lesions and testing track disability.